SEB Asset Management AB »

Abcellera Biologics shares owned by SEB Asset Management AB

Quarter-by-quarter ownership of Abcellera Biologics (ABCL) shares owned by SEB Asset Management AB from 13F filings

Historical chart of SEB Asset Management AB investment in Abcellera Biologics

Tip: Access up to 7 years of quarterly data

All positions including Abcellera Biologics held by SEB Asset Management AB consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Abcellera Biologics by SEB Asset Management AB

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.2M 340k 3.49

More positions owned by SEB Asset Management AB

NVIDIA Corporation (NVDA)
Apple (AAPL)
Astrazeneca Ord (AZN)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Broadcom (AVGO)
Alphabet Cap Stk Cl A (GOOGL)
Alphabet Cap Stk Cl C (GOOG)
Meta Platforms Cl A (META)
Eli Lilly & Co. (LLY)
JPMorgan Chase & Co. (JPM)
Johnson & Johnson (JNJ)
Mastercard Incorporated Cl A (MA)
Citigroup Com New (C)
Tesla Motors (TSLA)

View all positions for SEB Asset Management AB

Top funds holding Abcellera Biologics

Baker Bros. Advisors
Capital World Investors
Two Sigma Investments
TD Waterhouse Canada
Ubs Global Asset Management Americas
Leucadia National Corporation
UBS Group
Arrowpoint Asset Management
BlackRock
Driehaus Capital Management
Goldman Sachs Group
Bank of America Corporation
Alyeska Investment Group
Renaissance Technologies
Tudor Investment Corporation

View all funds holding Abcellera Biologics